IGC Pharma (IGC, Financial) has broadened its Phase 2 CALMA clinical trial by opening a new site at Tekton Research in Yukon, Oklahoma. This move is part of the company's strategy to enhance the diversity of its trial participants and tackle healthcare disparities in different regions. The Yukon site, located in the Oklahoma City metropolitan area, will focus on evaluating IGC-AD1 for managing agitation in patients with Alzheimer's dementia.
The selection of Tekton Research is notable due to its robust track record in conducting clinical studies across various therapeutic fields, including Alzheimer's, migraine, and vaccines. Leading the research efforts at the new site will be Dr. David McCoy, a board-certified neurologist who brings local expertise as a native of Oklahoma and a practitioner in Canadian County. This initiative aims to ensure a comprehensive assessment of the drug’s efficacy in managing Alzheimer's-related symptoms.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for IGC Pharma Inc (IGC, Financial) is $3.88 with a high estimate of $4.25 and a low estimate of $3.50. The average target implies an upside of 1,158.12% from the current price of $0.31. More detailed estimate data can be found on the IGC Pharma Inc (IGC) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, IGC Pharma Inc's (IGC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for IGC Pharma Inc (IGC, Financial) in one year is $0.41, suggesting a upside of 33.12% from the current price of $0.308. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the IGC Pharma Inc (IGC) Summary page.
